Relief Therapeutics Holding SA (OTCMKTS:RLFTF) Stock Falls 5% In a Week: Here is Why

December 21, 2021

Participation in major industry related investors conferences is almost always a good thing for any company and hence, it may be a good idea for investors to take a look at Relief Therapeutics Holding SA (OTCMKTS:RLFTF) stock today. Trading Data On Monday, RLFTF stock lowered by 1.23% to $0.0641 with more than 3 million shares, compared to its average volume of 5.43 million shares. The stock has moved within a…


Relief Therapeutics Holding SA (OTCMKTS:RLFTF) Stock Falls From The Recent Peak

October 14, 2021

Shares of Relief Therapeutics Holding SA (OTCMKTS:RLFTF) fell 13% after the biopharmaceutical company said the parent company of its US partner NRx Pharmaceuticals has submitted a revised Investigational New drug module. The submission to the US Food and Drug Administration is for the manufacturing of ZYESAMI(TM) (aviptadil). The module is to be used as part of the FDA’s review process supporting the ZYESAMI(TM) New Drug application. The documentation indicates that…


Relief Therapeutics Holding SA (OTCMKTS:RLFTF) Stock Falls 10% in a Week: But Why?

October 7, 2021

In the past week the Relief Therapeutics Holding SA (OTCMKTS:RLFTF) stock has had a pretty forgettable time in the market and has declined by as much as 10% amidst a selloff. However, at the same time, it cannot be denied that a correction in a stock can often be an opportunity as well and hence, it might be a good idea to figure that out. Yesterday, the company along with…


Relief Therapeutics Inc (OTCMKTS:RLFTF) Launches PKU GOLIKE(R) KRUNCH in Germany and Italy

September 10, 2021

Biopharmaceutical company, Relief Therapeutics Inc (OTCMKTS:RLFTF) on September 9, 2021, announced that APR Applied Pharma Research, the wholly owned subsidiary, has launched affiliates in Germany and Italy, PKU GOLIKE(R) KRUNCH, a convenient chewable tablet for the dietary management of phenylketonuria, a metabolic genetic disorder. Paolo Galfetti, Chief Executive Officer of APR and President of Relief Europe, said that the firm is addressing a vital need with flexible option for PKU….


Relief Therapeutics Holding AG (RLFTF) Stock Trends Lower: Falls 13% in a Month

September 7, 2021

Although the Relief Therapeutics Holding AG (OTCMKTS:RLFTF) stock has been in focus among investors for many months, it has performed quite poorly over the course of the past month. During that period, the Relief stock has suffered from a steady selloff and tanked by as much as 13%. In this regard, it might be a good idea for investors to take a look at a key announcement from the company…


Relief Therapeutics Holding AG (OTCMKTS:RLFTF) Stock in Focus: How to Trade Now?

August 11, 2021

Pharmaceutical company focusing on acquisition, development, and commercialization of therapies for rare diseases, Acer Therapeutics, and Relief Therapeutics Holding AG (OTCMKTS:RLFTF) on August 9, 2021, announced the submission of a New Drug Application to the US FDA for ACER-001 (sodium phenylbutyrate) to treat Urea Cycle Disorders. A nitrogen-binding agent, ACER-001 is being utilized for use as adjunctive therapy in the chronic management of patients with UCDs. The company is expecting…


RELIEF Therapeutics Holding AG (OTCMKTS: RLFTF) Says Its Collaboration Partner Has Validated a Commercial Aviptadil Formulation

July 26, 2021

RELIEF Therapeutics Holding AG (OTCMKTS: RLFTF) has announced that the parent company of its US partner NRx Pharmaceuticals Inc. (NASDAQ: NRX) has confirmed the validation of a commercial aviptadil formulation for intravenous use. This will allow for high volume production with an expected one year or more stability under the ideal storage condition. NRx successfully validates new aviptadil formulation  NRx CEO Jonathan Javitt said, “When we began developing aviptadil for…


Relief Therapeutics Inc.’s (OTCMKTS: RLFTF) Partner, NRx Pharmaceuticals Inc. (NASDAQ: NRXP), Studying Aviptadil In COVID-19 Treatment

July 14, 2021

Relief Therapeutics Inc. (OTCMKTS: RLFTF) has announced that NRx Pharmaceuticals Inc. (NASDAQ: NRXP), its collaboration partner, and Quantum Leap Healthcare Collaborative have commenced patient treatment with inhaled Aviptadil in phase 2 adaptive platform trial, I-SPY COVID Trial, in enhancing treatment for critically and severely ill SARS-CoV-2 patients.  Relief Therapeutics’ flagship drug candidate evaluated for COVID-19 treatment  The company develops molecules-based clinical-stage programs with historical clinical testing and use for human…